IFPA ataskaita rodo, kad Lietuvos pacientai turi labai ilgai laukti naujų, inovatyvių vaistų.
Pharmaceutical Industries and Associations showed that Lithuania is at the endw of the lists comparing access of innovation therapies in 35 Europe countries. In 2016-2019 period we only approved (point at which the product gains access to the reimbursement list): 26% new innovative therapies out of 152 approved by EMA (EU mean 74 (49%).
Lithuania patients have to wait on average 780 days for new medicine in the meantine EU mean is 504 days. We are fourth from the back of the list just after Romania 883, Russia 815 and Bosnia 797.
Healthcare system is beneficial only when patients are able to get the best treatment they need.